133446-99-8

Basic information

• Product Name: 2-BROMOMETHYL-4-NITRO-BENZOIC ACID METHYL ESTER
• Synonyms: 2-BROMOMETHYL-4-NITRO-BENZOIC ACID METHYL ESTER;Methyl 2-(broMoMethyl)-4-nitrobenzoate;Lenalidomide Impurity 16
• CAS NO: 133446-99-8
• Molecular Formula: C₉H₈BrNO₄
• Molecular Weight: 274.08
• Mol File: 133446-99-8.mol
• Article Data: 34

Chemical Properties

• Boiling Point: 398.4±37.0 °C(Predicted)
• Appearance: /
• Density: 1.624±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-BROMOMETHYL-4-NITRO-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMOMETHYL-4-NITRO-BENZOIC ACID METHYL ESTER(133446-99-8)
• EPA Substance Registry System: 2-BROMOMETHYL-4-NITRO-BENZOIC ACID METHYL ESTER(133446-99-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-43
• Safety Statements: 36/37
• Hazardous Substances Data: 133446-99-8(Hazardous Substances Data)

Usage

Uses

Methyl 2-(Bromomethyl)-4-nitrobenzoate is used in the synthetic preparation of cyclic hydroxamic acid derivatives as histone deacetylase inhibitors with antitumor activity.

Upstream product

• 62621-09-4 methyl 2-methyl-4-nitrobenzoate 
• 1975-51-5 2-methyl-4-nitrobenzoic acid 
• 99584-16-4 2-methyl-4-nitro-benzoic acid amide 
• 89001-53-6 2-cyano-5-nitrotoluene 
• 99-52-5 2-methyl-4-nitro-benzenamine 
• 99548-55-7 4-bromo-2-methyl-benzoic acid methyl ester 

Downstream Products

• 924266-46-6 4-nitro-2-phenoxymethyl-benzoic acid methyl ester 
• 1214900-77-2 2-(2,4-Dimethoxybenzyl)-5-nitroisoindolin-1-one 
• 1056566-95-0 methyl 2-((N-(2-methoxy-2-oxoethyl)-4-methylphenylsulfonamido)methyl)-4-nitrobenzoate 
• 1190380-38-1 5-amino-2-methylisoindolin-1-one 
• 222036-66-0 5-amino-2,3-dihydro-1H-benzo[c]azol-1-one 

Relevant articles and documents

Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer

Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3–fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.

COMPOUNDS AND USES THEREOF

The present disclosure features compounds and methods useful for the treatment of BAF complex-related disorders.

COMPOUNDS AND USES THEREOF

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.